ArticleJournal of gastrointestinal cancer2026
Personalizing Postoperative Surveillance: A Risk-Stratified Predictive Model for Recurrence of Gastrointestinal Neuroendocrine Neoplasms.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCurrent Ki-67-based prognostic tools have limitations in stratifying recurrence risk for gastrointestinal neuroendocrine neoplasms (GI-NENs) after primary tumor resection (PTR), necessitating personalized predictive models to optimize surveillance.
methodsData from 316 GI-NEN patients undergoing PTR were analyzed. Variables selected via LASSO regression were incorporated into Cox and Random Survival Forest (RSF) models. A nomogram was constructed based on superior model, and cut-off scores stratified patients into three recurrence risk groups.
resultsThe RSF model showed superior accuracy (C-index: 0.854) with good discrimination and calibration. A nomogram integrating eight key predictors stratified patients into low-risk (n = 241), intermediate-risk (n = 57), and high-risk (n = 18) groups. The Kaplan-Meier curves among them were significantly distinct. High-risk group had a median recurrence-free survival of 11.4 months, with nearly all experiencing recurrence or progression within 26 months. Compared with traditional NET grading, this model reclassified some G2 patients into intermediateand even high-risk groups and down-stratified G3 patients with favorable prognoses into the intermediate-risk group.
conclusionsThis study developed and validated a risk-stratified model that effectively identifies postoperative recurrence risk in GI-NENs, enabling tailored surveillance. High-risk patients require intensive follow-up every 2-3 months and early adjuvant intervention. Low-risk patients can safely extend to annually. Most intermediate-risk patients may recieve follow-up every 6-12 months, though G3 patients near the high-risk threshold may still require surveillance every 3-6 months. This model facilitates personalized follow-up to improve long-term outcomes.
Indexed as
Identifiers
42658380What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.